Clonal or inflammatory interleukin-6 levels in essential thrombocythemia

Cacciola, Rossella; Cipolla, Antonio; Francesco, Ernesto Di; Seria, Elisa; Torre, María José de la; Cacciola, Emma

doi:10.1016/j.exphem.2013.05.189

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Indeed, IL-6 is one of the cytokines related to megakaryocytic development, which exerts its effect through binding to a cell surface receptor, IL-6Ra, and a signal transducing unit, gp130, especially in JAK2V617F -positive patients. 33 In addition, Cacciola et al 34 confirmed that IL-6 may facilitate clonal expansion in JAK2V617F mutated patients with ET and represent an unfavorable prognostic indicator. Indeed, our study confirmed significantly higher concentrations of IL-6 in all the patients with ET compared to healthy individuals and even more importantly, higher concentrations in the patients with ET carrying the mutation as opposed to those who do not, which falls in line with the previous reports.…”

Section: Discussionmentioning

confidence: 96%

Plasma Concentrations of Protein Z and Protein Z-Dependent Protease Inhibitor in Patients With Essential Thrombocythemia

Szumowska

Galar

Bołkuń

et al. 2016

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

The pathological consequences of decreased protein Z (PZ) and/or Z-dependent protease inhibitor (ZPI) levels remain as yet unclear, despite a growing body of evidence which supports their involvement in an increased thrombotic risk. The purpose of the present study was 2-fold: to evaluate plasma concentrations of protein Z and ZPI in patients with essential thrombocythemia (ET) and to determine their significance in thrombotic complications. The median (range) plasma concentrations of PZ in our patients with ET were lower, but not significantly, than in healthy individuals: PZ (1.42 µg/mL, 0.36-3.14 µg/mL vs 1.6 µg/mL, 0.75-2.56 µg/mL, P = .08). On the other hand, the median (range) plasma concentrations of ZPI in the said patients with ET were meaningfully lower than in the reference group: ZPI (3.22 µg/mL, 0.85-6.97 µg/mL vs 4.41 µg/mL, 1.63-7.83 µg/mL, P = .0004). More importantly, the study revealed a statistically significant lower concentration of PZ and ZPI in patients with the presence of the JAK2V617F mutation relative to patients without the mutation, for PZ: 1.38 µg/mL, 0.36-2.6 µg/mL versus 1.63 µg/mL, 0.88-3.14 µg/mL, P = .03, and ZPI 2.89 µg/mL, 0.85-5.91 µg/mL versus 3.61 µg/mL, 1.53-6.97 µg/mL, P = .002. Additionally, significant differences between the concentrations of PZ and ZPI were found in patients with venous thrombotic episodes compared to healthy individuals, for PZ: 1.23 µg/mL, 0.82-1.99 µg/mL versus 1.6 µg/mL, 0.75-2.56 µg/mL, P = .043, and ZPI: 2.42 µg/mL, 0.85-4.21 µg/mL versus 4.41 µg/mL, 1.63-7.83 µg/mL, P < .0001. To recapitulate, our results suggest that the deficiency of PZ may increase tendency to thrombosis in patients with ET.

show abstract

Section: Discussionmentioning

confidence: 96%